MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

REGENXBIO Inc

Deschisă

SectorSănătate

8.97 2.16

Rezumat

Modificarea prețului

24h

Curent

Minim

8.74

Maxim

9.3

Indicatori cheie

By Trading Economics

Venit

8.4M

-51M

Vânzări

-3M

21M

EPS

-1.01

Marjă de profit

-241.284

Angajați

353

EBITDA

17M

-38M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+253.26% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

37M

334M

Deschiderea anterioară

6.81

Închiderea anterioară

8.97

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

REGENXBIO Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 apr. 2025, 09:30 UTC

Top știri

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Comparație

Modificare preț

REGENXBIO Inc Așteptări

Obiectiv de preț

By TipRanks

253.26% sus

Prognoză pe 12 luni

Medie 32.5 USD  253.26%

Maxim 50 USD

Minim 12 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruREGENXBIO Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

10

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

7.82 / N/ASuport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.